KR102176883B1 - Composition for skin regeneration, anti-wrinkle, or wound healing containing Prunus persica resin - Google Patents
Composition for skin regeneration, anti-wrinkle, or wound healing containing Prunus persica resin Download PDFInfo
- Publication number
- KR102176883B1 KR102176883B1 KR1020200054728A KR20200054728A KR102176883B1 KR 102176883 B1 KR102176883 B1 KR 102176883B1 KR 1020200054728 A KR1020200054728 A KR 1020200054728A KR 20200054728 A KR20200054728 A KR 20200054728A KR 102176883 B1 KR102176883 B1 KR 102176883B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- ppm
- composition
- wound
- resin
- Prior art date
Links
- 239000011347 resin Substances 0.000 title claims abstract description 63
- 229920005989 resin Polymers 0.000 title claims abstract description 63
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 230000029663 wound healing Effects 0.000 title claims abstract description 23
- 230000036560 skin regeneration Effects 0.000 title abstract description 25
- 235000011446 Amygdalus persica Nutrition 0.000 title abstract description 5
- 240000005809 Prunus persica Species 0.000 title abstract description 5
- 230000001153 anti-wrinkle effect Effects 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 53
- 206010052428 Wound Diseases 0.000 claims abstract description 46
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 46
- 239000002537 cosmetic Substances 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 230000036541 health Effects 0.000 claims abstract description 12
- 235000013376 functional food Nutrition 0.000 claims abstract description 11
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 17
- BNMGUJRJUUDLHW-HCZMHFOYSA-N Madecassoside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(C[C@@H](O)[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O BNMGUJRJUUDLHW-HCZMHFOYSA-N 0.000 claims description 16
- BNMGUJRJUUDLHW-HLUHVYOBSA-N Madecassoside Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](CO[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O BNMGUJRJUUDLHW-HLUHVYOBSA-N 0.000 claims description 16
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 claims description 16
- 229940090813 madecassoside Drugs 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 13
- 230000005855 radiation Effects 0.000 claims description 10
- 241000167550 Centella Species 0.000 claims description 5
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims description 4
- 230000035876 healing Effects 0.000 claims description 4
- 241000220259 Raphanus Species 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 22
- 230000006872 improvement Effects 0.000 description 35
- 210000003491 skin Anatomy 0.000 description 19
- 238000011084 recovery Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 229940059958 centella asiatica extract Drugs 0.000 description 11
- 239000006210 lotion Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- -1 foundation Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 239000001974 tryptic soy broth Substances 0.000 description 4
- 108010050327 trypticase-soy broth Proteins 0.000 description 4
- 244000144730 Amygdalus persica Species 0.000 description 3
- 244000146462 Centella asiatica Species 0.000 description 3
- 235000004032 Centella asiatica Nutrition 0.000 description 3
- 235000006040 Prunus persica var persica Nutrition 0.000 description 3
- 244000088415 Raphanus sativus Species 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- RZSCFTDHFNHMOR-UHFFFAOYSA-N n-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]pyridine-3-carboxamide;1,1-dimethyl-3-(4-propan-2-ylphenyl)urea Chemical compound CC(C)C1=CC=C(NC(=O)N(C)C)C=C1.FC1=CC(F)=CC=C1NC(=O)C1=CC=CN=C1OC1=CC=CC(C(F)(F)F)=C1 RZSCFTDHFNHMOR-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
피부 재생, 주름 개선, 또는 상처 치유용 조성물에 관한 것이다.It relates to a composition for skin regeneration, wrinkle improvement, or wound healing.
복사나무 진액은 약간 노란색의 점성을 띠고 있으며, 마르면 단단한 형태로 바뀐다. 중국 등 아시아에서는 도교라고도 불리며, 단백질과 콜라겐 성분이 풍부해 식용으로도 섭취하고, 약재로도 활용되고 있다.Radiant tree extract has a slightly yellowish consistency, and turns into a hard form when dried. It is also called Taoism in China and other Asian countries, and is rich in protein and collagen, so it is consumed for food and used as a medicine.
비특허문헌 1은 피치검 유래 올리고당이 항산화 활성 및 항박테리아 활성을 가지는 것을 개시하고 있다.Non-Patent Document 1 discloses that the oligosaccharide derived from pitch gum has antioxidant activity and antibacterial activity.
그러나, 복사나무 수지의 피부 재생 및 상처 회복 효과에 대한 연구는 전무하다.However, there are no studies on the effects of radix tree resin on skin regeneration and wound healing.
복사나무 수지, 또는 그의 추출물을 유효성분으로 함유하는 피부 재생, 주름 개선, 또는 상처 개선용 화장료 조성물을 제공한다.It provides a cosmetic composition for skin regeneration, wrinkle improvement, or wound improvement, containing a radish tree resin or an extract thereof as an active ingredient.
복사나무 수지, 또는 그의 추출물을 유효성분으로 함유하는 피부 재생, 주름 개선, 또는 상처 치유용 약학 조성물을 제공한다.It provides a pharmaceutical composition for skin regeneration, wrinkle improvement, or wound healing containing a radish tree resin, or an extract thereof, as an active ingredient.
복사나무 수지, 또는 그의 추출물을 유효성분으로 함유하는 피부 재생, 주름 개선, 또는 상처 개선용 건강기능식품 조성물을 제공한다.It provides a health functional food composition for skin regeneration, wrinkle improvement, or wound improvement, containing a copy tree resin, or an extract thereof as an active ingredient.
유효한 양의 상기한 조성물을 개체에게 적용 또는 투여하는 단계를 포함하는 피부 재생, 주름 개선, 또는 상처 개선 방법을 제공한다.It provides a method of skin regeneration, wrinkle improvement, or wound improvement comprising the step of applying or administering to a subject an effective amount of the above composition.
일 양상은 복사나무 수지, 또는 그의 추출물을 유효성분으로 함유하는 피부 재생, 주름 개선, 또는 상처 개선용 화장료 조성물을 제공한다.One aspect provides a cosmetic composition for skin regeneration, wrinkle improvement, or wound improvement, comprising a radix tree resin or an extract thereof as an active ingredient.
일 실시예에서, 복사나무 수지는 피부를 재생하고, 그에 따라 주름을 개선하며, 상처를 회복시키는 효과가 우수함을 확인하였다.In one embodiment, it was confirmed that the radiant tree resin has an excellent effect of regenerating the skin, improving wrinkles and healing wounds accordingly.
“복사나무 수지(peach resin)”는 복사나무(Prunus Persica)로부터 얻어지는 수지를 의미하며, 용어 “복숭아 수지”, “복사나무 검”, “피치검”, “도교”와 혼용될 수 있다. 복사나무 수지는 복사나무 진액 자체, 또는 복사나무 진액으로부터 얻은 물질일 수 있고, 예를 들어 복사나무 진액을 분리 추출해 얻은 다당류를 주성분으로 하는 검류일 수 있다. “Peach resin” refers to a resin obtained from Prunus Persica , and can be used interchangeably with the terms “peach resin”, “copy tree sword”, “pitch gum” and “Taoism”. The radiant tree resin may be a radiant tree extract itself, or a substance obtained from the radiant tree extract, and may be, for example, a gum based on a polysaccharide obtained by separating and extracting the radiant tree extract.
본 명세서에서, 복사나무 수지는 복사나무 수지 자체, 또는 복사나무 수지의 추출물일 수 있다. 상기 “추출물”은 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물, 또는 이들 조정제물 또는 정제물, 이를 분획한 분획물을 포함할 수 있다. 일 구체예에서, 상기 복사나무 수지는 복사나무 수지 추출물(Prunus Persica (Peach) Resin Extract)이다. 상기 복사나무 수지 추출물은 복사나무 수지로부터 통상적인 용매를 사용하여 추출한 추출물일 수 있다. 예를 들어, 상기 추출 용매는 에탄올 등의 알코올일 수 있다. 다른 구체예에서, 상기 복사나무 수지는 복사나무 수지 추출액의 농축액이다. In the present specification, the copy tree resin may be a copy tree resin itself, or an extract of the copy tree resin. The "extract" may include an extract, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, or a crude product or purified product thereof, and a fraction obtained by fractionating the product. In one embodiment, the radiant tree resin is Prunus Persica (Peach) Resin Extract. The radiant tree resin extract may be an extract extracted from the radiant tree resin using a conventional solvent. For example, the extraction solvent may be an alcohol such as ethanol. In another embodiment, the radiant tree resin is a concentrate of the radiant tree resin extract.
“유효성분으로 함유”는 상기에서 언급한 효과를 나타낼 수 있는 정도로 복사나무 수지, 그의 추출물, 또는 그의 추출물의 농축물이 첨가되는 것을 의미하고, 약물전달 및 안정화를 위하여 다양한 성분을 부성분으로 첨가하여 다양한 형태로 포뮬레이션(formulation)되는 것을 포함하는 의미이다.“Containing as an active ingredient” means that radix tree resin, its extract, or a concentrate of its extract is added to the extent that it can exhibit the above-mentioned effects, and various ingredients are added as auxiliary ingredients for drug delivery and stabilization. It is meant to include being formulated in various forms.
“피부 재생”은 피부의 일부분이 소실되었거나 손상되었을 경우 그 부분을 보충하거나 피부 세포의 증식 및 이동을 증진시키는 모든 작용을 의미할 수 있다. 피부가 재생됨에 따라 주름 개선 효과가 나타날 수 있다."Skin regeneration" may mean any action that supplements a part of the skin when it is lost or damaged or promotes the proliferation and migration of skin cells. As the skin regenerates, wrinkles may improve.
"주름"은 피부의 탄력성이 상실되어 느슨해진 상태를 의미하며, 예를 들면 피부가 접히는 것일 수 있다."Wrinkle" refers to a state in which the elasticity of the skin is lost and loosened, for example, the skin may be folded.
“개선”은 상태의 완화 또는 치료와 관련된 파라미터, 예를 들면 증상의 정도를 적어도 감소시키는 모든 행위를 의미할 수 있다.“Improvement” may refer to any action that at least reduces the severity of a parameter related to the alleviation or treatment of the condition, eg symptom.
“주름 개선”은 얼굴이나 신체의 주름을 옅어지게 하거나 감소시키는 모든 작용을 의미할 수 있다.“Wrinkle improvement” can mean any action that thins or reduces wrinkles on the face or body.
“상처”는 “창상”이라고도 하며, 생체의 손상을 의미한다. 상기 손상은 물리적 손상, 방사선, 화학물질에 의한 자극, 미생물의 증식 등 외부 요인, 스트레스 등의 내부 요인에 의한 것일 수 있으나, 이에 한정되지 않는다. 상기 상처는 절창, 자창, 할창, 좌창, 열창, 사창, 교창 등 모든 종류의 상처를 포함할 수 있다.“Wound” is also referred to as “wound” and means damage to a living body. The damage may be due to external factors such as physical damage, radiation, stimulation by chemical substances, proliferation of microorganisms, and internal factors such as stress, but is not limited thereto. The wound may include all kinds of wounds, such as a cut window, a javelin, a halved window, an acne, a fissure, a slit, and a school window.
“상처 개선”은 얼굴이나 신체의 상처를 옅어지게 하거나 정도를 감소시키는 모든 작용을 의미할 수 있다.“Wound improvement” can mean any action that lightens or reduces the severity of a face or body wound.
“상처 치유”는 상처를 회복하는 일련의 생체반응을 의미할 수 있다.“Wound healing” can refer to a series of biological reactions to repair the wound.
상기 피부 재생, 주름 개선, 상처 개선, 또는 상처 치유의 원인은 제한이 없으나, 예를 들어 피부 세포의 이동 또는 증식에 의한 것일 수 있다.The cause of skin regeneration, wrinkle improvement, wound improvement, or wound healing is not limited, but may be due to, for example, migration or proliferation of skin cells.
상기 복사나무 수지, 또는 그의 추출물은 조성물에 대해 1 내지 100,000 ppm, 1 내지 50,000 ppm, 1 내지 10,000 ppm, 1 내지 5,000 ppm, 1 내지 3,000 ppm, 1 내지 2,000 ppm, 1 내지 1,000 ppm, 1 내지 500 ppm, 1 내지 100 ppm, 10 내지 10,000 ppm, 10 내지 5,000 ppm, 10 내지 3,000 ppm, 10 내지 2,000 ppm, 10 내지 1,000 ppm, 10 내지 500 ppm, 또는 10 내지 100 ppm의 농도로 함유될 수 있다. 복사나무 수지의 농도가 지나치게 낮을 경우 목적하는 피부 재생, 주름 개선, 상처 개선 효과가 나타나지 않을 수 있다. 복사나무 수지의 농도가 100,000 ppm을 초과하는 경우, 냄새에 의한 불편함이 발생할 수 있다.The radiation tree resin, or an extract thereof, is 1 to 100,000 ppm, 1 to 50,000 ppm, 1 to 10,000 ppm, 1 to 5,000 ppm, 1 to 3,000 ppm, 1 to 2,000 ppm, 1 to 1,000 ppm, 1 to 500 ppm for the composition. ppm, 1 to 100 ppm, 10 to 10,000 ppm, 10 to 5,000 ppm, 10 to 3,000 ppm, 10 to 2,000 ppm, 10 to 1,000 ppm, 10 to 500 ppm, or 10 to 100 ppm. If the concentration of the radiant tree resin is too low, the intended skin regeneration, wrinkle improvement, and wound improvement effects may not appear. If the concentration of radiant tree resin exceeds 100,000 ppm, discomfort due to odor may occur.
상기 화장료 조성물은 병풀추출물, 마데카소사이드(Madecassoside), 및 스타필로코커스 에피데르미디스(Staphylococcus epidermidis) 균주 배양액 중 어느 하나 이상을 더 함유할 수 있다.The cosmetic composition may further contain any one or more of Centella asiatica extract, Madecassoside, and Staphylococcus epidermidis strain culture solution.
“병풀추출물(Centella Asiatica Extract)”은 “센텔라 추출물”이라고도 하며, 병풀(Centella Asiatica)의 전초에서 추출한 추출물이다.“ Centella Asiatica Extract” is also called “Centella Extract”, and is an extract extracted from the outpost of Centella Asiatica .
일 실시예에서, 복사나무 수지 및 병풀추출물의 조합을 사용할 경우 시너지적 상처 회복 효과가 나타남을 확인하였다. 구체적으로, 복사나무 수지 100 ppm 및 병풀추출물 10 ppm을 함께 처리할 경우 각각을 단독으로 처리한 경우에 비해 시너지적 상처 회복 효과가 우수함을 확인하였다.In one embodiment, it was confirmed that a synergistic wound healing effect appeared when using a combination of radix tree resin and centella asiatica extract. Specifically, it was confirmed that when 100 ppm of radix tree resin and 10 ppm of centella asiatica were treated together, the synergistic wound recovery effect was excellent compared to the case where each was treated alone.
상기 병풀추출물은 조성물에 대해 1 내지 100,000 ppm, 1 내지 50,000 ppm, 1 내지 10,000 ppm, 1 내지 5,000 ppm, 1 내지 3,000 ppm, 1 내지 2,000 ppm, 1 내지 1,000 ppm, 1 내지 500 ppm, 또는 1 내지 100 ppm의 농도로 함유될 수 있다.The centella extract is 1 to 100,000 ppm, 1 to 50,000 ppm, 1 to 10,000 ppm, 1 to 5,000 ppm, 1 to 3,000 ppm, 1 to 2,000 ppm, 1 to 1,000 ppm, 1 to 500 ppm, or 1 to It may be contained in a concentration of 100 ppm.
상기 조성물은 복사나무 수지 및 병풀추출물을 1:1 내지 100:1의 중량비, 예를 들어 10:1의 중량비로 함유할 수 있으나, 이에 한정되지 않는다.The composition may contain the radix tree resin and centella asiatica extract in a weight ratio of 1:1 to 100:1, for example, in a weight ratio of 10:1, but is not limited thereto.
“마데카소사이드(Madecassoside)”는 병풀(Centella Asiatica)에서 추출된 화합물이다.“Madecassoside” is a compound extracted from Centella Asiatica .
상기 스타필로코커스 에피데르미디스(Staphylococcus epidermidis) 균주는 공지의 균주를 사용할 수 있다. 예를 들어, 스타필로코커스 에피데르미디스(Staphylococcus epidermidis) ST-6 균주(수탁번호: KCCM12551P)일 수 있으나, 이에 한정되지 않는다. 상기 스타필로코커스 에피데르미디스(Staphylococcus epidermidis) 균주 배양액은 스타필로코커스 에피데르미디스(Staphylococcus epidermidis) 균주를 TSB(Tryptic soy broth) 배지에서 배양한 배양액일 수 있으나, 이에 한정되지 않는다.The Staphylococcus epidermidis strain may be a known strain. For example, it may be a Staphylococcus epidermidis ST-6 strain (accession number: KCCM12551P), but is not limited thereto. The Staphylococcus epidermidis strain culture solution may be a culture solution obtained by culturing the Staphylococcus epidermidis strain in TSB (Tryptic soy broth) medium, but is not limited thereto.
일 실시예에서, 복사나무 수지, 병풀추출물, 마데카소사이드, 및 스타필로코커스 에피데르미디스(Staphylococcus epidermidis) 균주 배양액의 조합을 사용할 경우 시너지적 상처 회복 효과가 나타남을 확인하였다. 구체적으로, 복사나무 수지 100 ppm, 병풀추출물 10 ppm, 마데카소사이드 10 ppm 및 스타필로코커스 에피데르미디스(Staphylococcus epidermidis) 균주 배양액 1%(v/v)를 함께 처리할 경우 각각을 단독으로 처리한 경우에 비해 시너지적 상처 회복 효과가 우수함을 확인하였다.In one embodiment, it was confirmed that a synergistic wound healing effect was exhibited when using a combination of a radiation tree resin, centella asiatica extract, madecassoside, and Staphylococcus epidermidis strain culture solution. Specifically, when treated with 100 ppm of radish tree resin, 10 ppm of centella asiatica extract, 10 ppm of madecassoside, and 1% (v/v) of the strain culture medium of Staphylococcus epidermidis Compared to one case, it was confirmed that the synergistic wound healing effect was superior.
상기 마데카소사이드는 조성물에 대해 1 내지 100,000 ppm, 1 내지 50,000 ppm, 1 내지 10,000 ppm, 1 내지 5,000 ppm, 1 내지 3,000 ppm, 1 내지 2,000 ppm, 1 내지 1,000 ppm, 1 내지 500 ppm, 또는 1 내지 100 ppm의 농도로 함유될 수 있다.The madecassoside is 1 to 100,000 ppm, 1 to 50,000 ppm, 1 to 10,000 ppm, 1 to 5,000 ppm, 1 to 3,000 ppm, 1 to 2,000 ppm, 1 to 1,000 ppm, 1 to 500 ppm, or 1 It may be contained in a concentration of to 100 ppm.
상기 스타필로코커스 에피데르미디스(Staphylococcus epidermidis) 균주 배양액은 조성물에 대해 0.01 내지 5%(v/v), 0.01 내지 3%(v/v), 0.01 내지 1%(v/v), 0.1 내지 5%(v/v), 0.1 내지 3%(v/v), 또는 0.1 내지 1%(v/v)의 농도로 함유될 수 있다.The Staphylococcus epidermidis strain culture solution is 0.01 to 5% (v/v), 0.01 to 3% (v/v), 0.01 to 1% (v/v), 0.1 to It may be contained in a concentration of 5% (v/v), 0.1 to 3% (v/v), or 0.1 to 1% (v/v).
상기 화장료 조성물은 화장수(스킨로션), 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양 로션, 마사지크림, 영양 크림, 모이스쳐 크림, 핸드크림, 파운데이션, 에센스, 영양 에센스, 팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션, 바디클렌저, 현탁액, 겔, 분말, 페이스트, 마스크팩, 마스크시트 또는 에어로졸 조성물의 제형으로 제조될 수 있으나, 이에 한정되지 않는다. 이러한 제형의 조성물은 당해 분야에서 통상적인 방법에 따라 제조될 수 있다.The cosmetic composition is a lotion (skin lotion), skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, foundation, essence, nutrition essence, pack, It may be prepared in the form of soap, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, suspension, gel, powder, paste, mask pack, mask sheet, or aerosol composition, but is not limited thereto. Compositions of these formulations can be prepared according to methods conventional in the art.
상기 화장료 조성물은 화장품학적으로 허용가능한 부형제 또는 담체를 더 포함할 수 있다. 상기 화장품학적으로 허용가능한 부형제 또는 담체의 종류는 제형 및 목적에 따라 다양하며, 통상적인 성분으로 예를 들어 물, 계면활성제, 알코올, 유분, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 한정되지 않는다. 상기 부형제 또는 담체의 배합량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 당업자가 용이하게 결정 가능하다.The cosmetic composition may further include a cosmetically acceptable excipient or carrier. The types of cosmetically acceptable excipients or carriers vary according to the formulation and purpose, and as usual ingredients, for example, water, surfactant, alcohol, oil, thickener, chelating agent, colorant, preservative, fragrance, etc. It can, but is not limited thereto. The blending amount of the excipient or carrier can be easily determined by a person skilled in the art within a range that does not impair the object and effect of the present invention.
다른 양상은 복사나무 수지, 또는 그의 추출물을 유효성분으로 함유하는 피부 재생, 주름 개선, 또는 상처 치유용 약학 조성물을 제공한다.Another aspect provides a pharmaceutical composition for skin regeneration, wrinkle improvement, or wound healing comprising a radix tree resin, or an extract thereof, as an active ingredient.
여기에서, “복사나무 수지”, “유효성분으로 함유”, “피부 재생”, “주름 개선”, “상처 치유”에 대한 설명은 전술한 바와 같다.Here, the explanations for “Radiation Tree Resin”, “Containing as an active ingredient”, “Skin regeneration”, “Wrinkle improvement”, and “Wound healing” are as described above.
상기 복사나무 수지, 또는 그의 추출물은 조성물에 대해 1 내지 100,000 ppm, 1 내지 50,000 ppm, 1 내지 10,000 ppm, 1 내지 5,000 ppm, 1 내지 3,000 ppm, 1 내지 2,000 ppm, 1 내지 1,000 ppm, 1 내지 500 ppm, 1 내지 100 ppm, 10 내지 10,000 ppm, 10 내지 5,000 ppm, 10 내지 3,000 ppm, 10 내지 2,000 ppm, 10 내지 1,000 ppm, 10 내지 500 ppm, 또는 10 내지 100 ppm의 농도로 함유될 수 있다. 복사나무 수지, 또는 그의 추출물의 농도가 지나치게 낮을 경우 목적하는 피부 재생, 주름 개선, 상처 개선 효과가 나타나지 않을 수 있다. 복사나무 수지, 또는 그의 추출물의 농도가 100,000 ppm을 초과하는 경우, 냄새에 의한 불편함이 발생할 수 있다.The radiation tree resin, or an extract thereof, is 1 to 100,000 ppm, 1 to 50,000 ppm, 1 to 10,000 ppm, 1 to 5,000 ppm, 1 to 3,000 ppm, 1 to 2,000 ppm, 1 to 1,000 ppm, 1 to 500 ppm for the composition. ppm, 1 to 100 ppm, 10 to 10,000 ppm, 10 to 5,000 ppm, 10 to 3,000 ppm, 10 to 2,000 ppm, 10 to 1,000 ppm, 10 to 500 ppm, or 10 to 100 ppm. When the concentration of the radix tree resin or its extract is too low, the desired effect of skin regeneration, wrinkle improvement, and wound improvement may not appear. When the concentration of the radix tree resin or its extract exceeds 100,000 ppm, discomfort due to odor may occur.
상기 약학 조성물은 병풀추출물, 마데카소사이드(Madecassoside), 및 스타필로코커스 에피데르미디스(Staphylococcus epidermidis) 균주 배양액 중 어느 하나 이상을 더 함유할 수 있다.The pharmaceutical composition may further contain any one or more of Centella asiatica extract, Madecassoside, and Staphylococcus epidermidis strain culture solution.
여기에서, “병풀추출물”, “마데카소사이드”, “스타필로코커스 에피데르미디스(Staphylococcus epidermidis) 균주 배양액” 및 그의 함량에 대한 설명은 전술한 바와 같다.Here, the description of “central grass extract”, “madecassoside”, “ Staphylococcus epidermidis strain culture solution” and its contents are as described above.
상기 약학 조성물은 경구 또는 비경구 투여 제형으로 제형화될 수 있다. 경구 투여 제형은 과립제, 산제, 액제, 정제, 캅셀제, 건조시럽제, 또는 그 조합일 수 있다. 비경구 투여 제형은 주사제 또는 피부 외용제일 수 있다. 상기 약학 조성물은 약학적으로 허용가능한 희석제 또는 담체를 더 포함할 수 있다. 상기 약학적으로 허용가능한 희석제 또는 담체의 종류는 제형 및 목적에 따라 다양하다. 상기 희석제는 유당, 옥수수 전분, 대두유, 미정질 셀룰로오스, 또는 만니톨, 활택제로는 스테아린산 마그네슘, 탈크, 또는 그 조합일 수 있다. 상기 담체는 부형제, 붕해제, 결합제, 활택제, 또는 그 조합일 수 있다. 상기 부형제는 미결정 셀룰로오즈, 유당, 저치환도 히드록시셀룰로오즈, 또는 그 조합일 수 있다. 상기 붕해제는 카르복시메틸셀룰로오스 칼슘, 전분글리콜산 나트륨, 무수인산일수소 칼슘, 또는 그 조합일 수 있다. 상기 결합제는 폴리비닐피롤리돈, 저치환도 히드록시프로필셀룰로오즈, 히드록시프로필셀룰로오즈, 또는 그 조합일 수 있다. 상기 활택제는 스테아린산 마그네슘, 이산화규소, 탈크, 또는 그 조합일 수 있다. 상기 희석제 또는 담체의 배합량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 당업자가 용이하게 결정 가능하다.The pharmaceutical composition may be formulated as an oral or parenteral dosage form. The oral dosage form may be a granule, powder, liquid, tablet, capsule, dry syrup, or a combination thereof. The parenteral dosage form may be an injection or an external preparation for the skin. The pharmaceutical composition may further include a pharmaceutically acceptable diluent or carrier. The kind of the pharmaceutically acceptable diluent or carrier varies depending on the formulation and purpose. The diluent may be lactose, corn starch, soybean oil, microcrystalline cellulose, or mannitol, and as a lubricant, magnesium stearate, talc, or a combination thereof. The carrier may be an excipient, a disintegrant, a binder, a lubricant, or a combination thereof. The excipient may be microcrystalline cellulose, lactose, low-substituted hydroxycellulose, or a combination thereof. The disintegrant may be calcium carboxymethylcellulose, sodium starch glycolate, anhydrous calcium monohydrogen phosphate, or a combination thereof. The binder may be polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, or a combination thereof. The lubricant may be magnesium stearate, silicon dioxide, talc, or a combination thereof. The blending amount of the diluent or carrier can be easily determined by a person skilled in the art within a range that does not impair the object and effect of the present invention.
일 구체예에서, 상기 약학 조성물은 피부 외용제일 수 있다. 상기 피부 외용제는 크림, 겔, 연고, 피부 유화제, 피부 현탁액, 경피전달성 패치, 약물 함유 붕대, 로션 등의 제형으로 제조될 수 있으나, 이에 한정되지 않는다. 상기 피부 외용제는 통상 화장품이나 의약품 등의 피부 외용제에 사용되는 성분, 예를 들면 수성성분, 유성성분, 분말성분, 알코올류, 보습제, 증점제, 자외선흡수제, 미백제, 방부제, 산화방지제, 계면활성제, 향료, 색제, 각종 피부 영양제, 또는 이들의 조합과 필요에 따라서 적절하게 배합될 수 있다. 상기 피부 외용제는, 에데트산이나트륨, 에데트산삼나트륨, 시트르산나트륨, 폴리인산나트륨, 메타인산나트륨, 글루콘산 등의 금속봉쇄제, 카페인, 탄닌, 벨라파밀, 감초추출물, 글라블리딘, 칼린의 과실의 열수추출물, 각종생약, 아세트산토코페롤, 글리틸리틴산, 트라넥삼산 및 그 유도체 또는 그 염등의 약제, 비타민 C, 아스코르브산인산마그네슘, 아스코르브산글루코시드, 알부틴, 코지산, 글루코스, 프룩토스, 트레할로스 등의 당류등도 적절하게 배합할 수 있다. 상기 피부 외용제에 사용되는 성분의 배합량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 당업자가 용이하게 결정 가능하다.In one embodiment, the pharmaceutical composition may be an external preparation for skin. The external preparation for skin may be prepared in a formulation such as a cream, gel, ointment, skin emulsifier, skin suspension, transdermal delivery patch, drug-containing bandage, lotion, etc., but is not limited thereto. The above skin external preparations are ingredients commonly used in external preparations for skin such as cosmetics or pharmaceuticals, such as aqueous ingredients, oily ingredients, powder ingredients, alcohols, moisturizers, thickeners, ultraviolet absorbers, whitening agents, preservatives, antioxidants, surfactants, fragrances. , Colorants, various skin nutrients, or combinations thereof and may be appropriately formulated according to need. The external preparations for skin include metal sequestering agents such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid, caffeine, tannin, bellapamil, licorice extract, glavidine, and caline. Hot water extract of fruit, various herbal medicines, drugs such as tocopherol acetate, glytilithic acid, tranexamic acid and derivatives or salts thereof, vitamin C, magnesium ascorbate, glucoside ascorbic acid, arbutin, kojic acid, glucose, fructose, Sugars such as trehalose can also be appropriately blended. The amount of the ingredients used in the external preparation for skin can be easily determined by a person skilled in the art within a range that does not impair the object and effect of the present invention.
다른 양상은 복사나무 수지, 또는 그의 추출물을 유효성분으로 함유하는 피부 재생, 주름 개선, 또는 상처 개선용 건강기능식품 조성물을 제공한다.Another aspect provides a health functional food composition for skin regeneration, wrinkle improvement, or wound improvement, comprising a radix tree resin, or an extract thereof, as an active ingredient.
여기에서, “복사나무 수지”, “유효성분으로 함유”, “피부 재생”, “주름 개선”, “상처 개선”에 대한 설명은 전술한 바와 같다.Here, the explanations for “copy tree resin”, “contained as an active ingredient”, “skin regeneration”, “wrinkle improvement” and “wound improvement” are as described above.
상기 건강기능식품 조성물은 병풀추출물, 마데카소사이드(Madecassoside), 및 스타필로코커스 에피데르미디스(Staphylococcus epidermidis) 균주 배양액 중 어느 하나 이상을 더 함유할 수 있다.The health functional food composition may further contain any one or more of centella extract, Madecassoside, and Staphylococcus epidermidis strain culture solution.
여기에서, “병풀추출물”, “마데카소사이드”, “스타필로코커스 에피데르미디스(Staphylococcus epidermidis) 균주 배양액” 및 그의 함량에 대한 설명은 전술한 바와 같다.Here, the description of “central grass extract”, “madecassoside”, “ Staphylococcus epidermidis strain culture solution” and its contents are as described above.
상기 건강기능식품 조성물은 상기 복사나무 수지 또는 그의 추출물 단독, 또는 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합양은 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 명세서의 조성물은 원료에 대하여 15 중량부 이하의 양으로 첨가될 수 있다. 상기 건강기능식품의 종류에는 특별한 제한은 없다. 건강기능식품의 종류 중 음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 건강식품 조성물은 또한 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제, 또는 그 조합을 함유할 수 있다. 상기 건강기능식품 조성물은 또한, 천연 과일쥬스, 과일쥬스 음료, 야채 음료의 제조를 위한 과육, 또는 그 조합을 함유할 수 있다.The health functional food composition may be used alone or in combination with other foods or food ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health or therapeutic treatment). In general, when preparing food or beverage, the composition of the present specification may be added in an amount of 15 parts by weight or less based on the raw material. There is no particular limitation on the kind of the health functional food. Among the types of health functional foods, the beverage composition may contain various flavoring agents or natural carbohydrates as an additional component, like a conventional beverage. The natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the sweetener, natural sweeteners such as taumatin and stevia extract, and synthetic sweeteners such as saccharin and aspartame can be used. The health food composition may also be used in nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonated beverages. Carbonating agents used, or combinations thereof. The health functional food composition may also contain natural fruit juice, fruit juice beverage, pulp for the production of vegetable beverages, or a combination thereof.
다른 양상은 유효한 양의 상기한 조성물을 개체에게 적용 또는 투여하는 단계를 포함하는 피부 재생, 주름 개선, 또는 상처 개선 방법을 제공한다.Another aspect provides a method for skin regeneration, wrinkle improvement, or wound improvement comprising the step of applying or administering to a subject an effective amount of the above composition.
“개체”는 피부 재생, 주름 개선, 또는 상처 개선이 필요한 인간을 포함하는 모든 동물을 의미한다.“Individual” means any animal, including humans, in need of skin regeneration, wrinkle improvement, or wound improvement.
“적용”은 개체에게 소정의 물질의 효력이 미칠 수 있도록 상기 물질을 적절한 방법으로 개체에 접촉시키거나 개체에게 전달하는 모든 행위를 의미한다. 상기 적용은 피부에 도포하는 방식일 수 있다.“Apply” means any act of contacting or transferring the substance to an object in an appropriate way so that the effect of the substance can be exerted on the object. The application may be a method of applying to the skin.
“투여”는 개체의 원하는 부위로의 적어도 부분적 국소화를 초래하는 방법 또는 개체 내로 소정의 물질을 배치하는 것을 의미한다. 투여는 당업계에 알려진 방법에 의하여 투여될 수 있다. 투여는 예를 들면, 정맥내, 근육내, 경구, 경피(transdermal), 점막, 코안(intranasal), 기관내(intratracheal) 또는 피하 투여와 같은 경로로, 임의의 수단에 의하여 개체로 직접적으로 투여될 수 있다. 상기 투여는 전신적으로 또는 국부적으로 투여될 수 있다.“Administering” means placing a substance into a subject or a method that results in at least partial localization of the subject to a desired site. Administration may be administered by a method known in the art. Administration can be administered directly to a subject by any means, for example by routes such as intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal or subcutaneous administration. I can. The administration can be administered systemically or locally.
상기 적용 또는 투여량은 제제화 방법, 투여 방식, 개체의 연령, 체중, 성별, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있고, 당업자라면 이러한 요인들을 고려하여 적용 또는 투여량을 적절히 조절할 수 있다. 적용 또는 투여 횟수는 1일 1회 또는 임상적으로 용인가능한 부작용의 범위 내에서 2회 이상이 가능하고, 적용 또는 투여 부위에 대해서도 1개소 또는 2개소 이상에 적용 또는 투여할 수 있으며, 매일 또는 2 내지 5일 간격으로 총 적용 또는 투여 일수는 한번 치료 시 1일에서 30일까지 적용 또는 투여될 수 있다. 필요한 경우, 적정 시기 이후에 동일한 치료를 반복할 수 있다. 인간 이외의 동물에 대해서도, kg당 인간과 동일한 투여량으로 하거나, 또는 예를 들면 목적의 동물과 인간과의 기관(심장 등)의 용적비(예를 들면, 평균값) 등으로 상기의 투여량을 환산한 양을 투여할 수 있다.The application or dosage may be variously prescribed depending on factors such as formulation method, mode of administration, age, weight, sex, pathological condition, food, administration time, route of administration, excretion rate and response sensitivity of the individual, and those skilled in the art If so, the application or dosage can be appropriately adjusted in consideration of these factors. The number of times of application or administration may be once a day or two or more times within the range of clinically acceptable side effects, and may be applied or administered at one or two or more sites for the application or administration site, and daily or 2 The total number of days of application or administration at intervals of 5 to 5 days may be applied or administered from 1 to 30 days in a single treatment. If necessary, the same treatment can be repeated after an appropriate time period. For non-human animals, the same dose per kg as human or, for example, the volume ratio (e.g., average value) of the target animal and the human organ (heart, etc.) One amount can be administered.
이상 사용된 모든 기술용어는, 달리 정의되지 않는 이상, 관련 분야에서 당업자가 일반적으로 이해하는 바와 같은 의미로 사용된다.All technical terms used above, unless otherwise defined, are used in the same meaning as those of ordinary skill in the art generally understand.
일 양상에 따른 조성물은 복사나무 수지, 또는 그의 추출물을 함유함으로써 피부 재생, 주름 개선, 상처 개선, 또는 상처 치유 효과가 우수하다. 따라서, 피부 재생, 주름 개선, 상처 개선, 또는 상처 치유를 위한 화장료 조성물, 약학 조성물, 건강기능식품 조성물 등으로 사용될 수 있다.The composition according to an aspect is excellent in skin regeneration, wrinkle improvement, wound improvement, or wound healing effect by containing the radix tree resin, or an extract thereof. Therefore, it can be used as a cosmetic composition, pharmaceutical composition, health functional food composition, etc. for skin regeneration, wrinkle improvement, wound improvement, or wound healing.
도 1은 실험예 1에 따른 2시간 간격으로 측정한 상처 회복 결과를 나타낸 그래프이다.
도 2는 실험예 1에 따른 처리 24시간 후 상처 회복 결과를 나타낸 그래프이다.
도 3은 실험예 1에 따른 0시간 및 처리 24시간 후 상처 회복 결과를 나타낸 현미경 사진이다.
도 4는 실험예 2에 따른 2시간 간격으로 측정한 상처 회복 결과를 나타낸 그래프이다.
도 5는 실험예 2에 따른 2시간 간격으로 측정한 상처 회복 결과를 나타낸 그래프이다.
도 6은 실험예 2에 따른 처리 16시간 후 상처 회복 결과를 나타낸 그래프이다.
도 7은 실험예 2에 따른 0시간 및 처리 16시간 후 상처 회복 결과를 나타낸 현미경 사진이다.1 is a graph showing wound recovery results measured at 2 hour intervals according to Experimental Example 1.
2 is a graph showing wound recovery results after 24 hours of treatment according to Experimental Example 1.
3 is a micrograph showing the wound recovery results after 0 hours and 24 hours treatment according to Experimental Example 1.
4 is a graph showing wound recovery results measured at 2 hour intervals according to Experimental Example 2.
5 is a graph showing wound recovery results measured at 2 hour intervals according to Experimental Example 2.
6 is a graph showing wound recovery results after 16 hours of treatment according to Experimental Example 2.
7 is a micrograph showing the wound recovery results after 0 hours and 16 hours treatment according to Experimental Example 2.
이하 본 발명을 실시예를 통하여 보다 상세하게 설명한다. 그러나, 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.
실시예 1. 복사나무 수지의 준비Example 1. Preparation of radiant tree resin
70% 에탄올 200ml당 50g의 복사나무 수지를 넣고 72시간 추출하여 추출액을 얻었다. 상기 추출액을 농축기를 사용하여 1ml로 농축하여 농축액을 얻었다. 상기 복사나무 수지 추출액의 농축액을 하기 실험에서 사용하였다.Add 50g of copy tree resin per 200ml of 70% ethanol and extract for 72 hours to obtain an extract. The extract was concentrated to 1 ml using a concentrator to obtain a concentrate. The concentrate of the radix tree resin extract was used in the following experiment.
실험예 1 및 2. 피부 재생 및 상처 회복 효능 평가Experimental Examples 1 and 2. Evaluation of skin regeneration and wound healing efficacy
복사나무 수지의 피부 재생 및 상처 회복 효능을 평가하기 위하여, 세포 이동성 검정(cell migration assay)을 수행하였다.In order to evaluate the skin regeneration and wound healing efficacy of the rhizome resin, a cell migration assay was performed.
시험 물질 준비Preparation of test substances
실험예 1 및 실험예 2에 대해 하기 표 1과 같이 각각 시험 물질을 준비하였다. 하기 표 1에서, “ST-6”는 스타필로코커스 에피데르미디스(Staphylococcus epidermidis) ST-6 균주(수탁번호: KCCM12551P)를 TSB(Tryptic soy broth) 배지(BD Difco™)에서 배양한 배양액을 의미한다.For Experimental Example 1 and Experimental Example 2, test substances were prepared as shown in Table 1 below. In Table 1 below, “ST-6” refers to a culture solution obtained by culturing Staphylococcus epidermidis ST-6 strain (accession number: KCCM12551P) in TSB (Tryptic soy broth) medium (BD Difco™). it means.
(처리 시간)Experimental example
(Processing time)
(24 시간)Experimental Example 1
(24 hours)
(16 시간)Experimental Example 2
(16 hours)
실험 절차Experimental procedure
첫째 날, 96-웰 ImageLock™ 플레이트(No. 4379; Essen BioScience)에 Hs68 인간 섬유아세포를 2×104 세포/웰로 분주하였다. 실험은 90% cell confluent에서 진행하였다.On the first day, Hs68 human fibroblasts were aliquoted into 96-well ImageLock™ plates (No. 4379; Essen BioScience) at 2×10 4 cells/well. The experiment was conducted at 90% cell confluent.
둘째 날, WoundMaker™(Essen BioScience, USA)를 70% 에탄올 용액 45 ml으로 5분 동안 세척한 후, 증류수 45 ml로 5분 동안 세척하였다. 세척된 WoundMaker™(Essen BioScience, USA)를 사용하여 상기 플레이트 각 웰의 모든 세포층을 스크래치하였다. 배지를 제거하고, PBS로 세척하였다. 무혈청배지를 채운 후, 상기 표 1의 각 시험 물질을 처리하였다.On the second day, WoundMaker™ (Essen BioScience, USA) was washed with 45 ml of 70% ethanol solution for 5 minutes and then with 45 ml of distilled water for 5 minutes. Washed WoundMaker™ (Essen BioScience, USA) was used to scratch all cell layers of each well of the plate. The medium was removed and washed with PBS. After filling the serum-free medium, each test substance in Table 1 was treated.
셋째 날, IncuCyte ZOOM(Essen BioScience, USA) 프로그램을 사용하여 상처가 회복되는 정도를 2시간 간격으로 측정해 그래프화하였다. 또한, 기기 내의 현미경으로 측정된 세포 사진을 확인하여 상처 회복 정도를 육안으로 확인하였다.On the third day, using the IncuCyte ZOOM (Essen BioScience, USA) program, the degree of healing of the wound was measured and graphed at 2 hour intervals. In addition, the degree of wound healing was visually confirmed by checking the cell picture measured by the microscope inside the device.
실험 결과Experiment result
도 1은 실험예 1에 따른 2시간 간격으로 측정한 상처 회복 결과를 나타낸 그래프이다. 1 is a graph showing wound recovery results measured at 2 hour intervals according to Experimental Example 1.
도 2는 실험예 1에 따른 처리 24시간 후 상처 회복 결과를 나타낸 그래프이다.2 is a graph showing wound recovery results after 24 hours of treatment according to Experimental Example 1.
도 3은 실험예 1에 따른 0시간 및 처리 24시간 후 상처 회복 결과를 나타낸 현미경 사진이다.3 is a micrograph showing the wound recovery results after 0 hours and 24 hours treatment according to Experimental Example 1.
도 1 내지 도 3에서 볼 수 있듯이, 복사나무 수지를 처리할 경우 세포 이동에 의해 상처 회복 효과가 나타났다. 또한, 복사나무 수지를 병풀추출물과 함께 처리할 경우 시너지적 상처 회복 효과가 나타남을 확인하였다. 특히, 복사나무 수지 100 ppm 및 병풀추출물 10 ppm을 함께 처리할 경우 각각을 단독으로 처리한 경우에 비해 시너지적 상처 회복 효과가 우수함을 확인하였다.As can be seen in FIGS. 1 to 3, when the radiation tree resin is treated, a wound healing effect was exhibited by cell migration. In addition, it was confirmed that a synergistic wound recovery effect appeared when the radix tree resin was treated with centella asiatica extract. In particular, when treated with 100 ppm of radix tree resin and 10 ppm of centella asiatica extract, it was confirmed that the synergistic wound recovery effect was excellent compared to the case where each was treated alone.
도 4는 실험예 2에 따른 2시간 간격으로 측정한 상처 회복 결과를 나타낸 그래프이다.4 is a graph showing wound recovery results measured at 2 hour intervals according to Experimental Example 2.
도 5는 실험예 2에 따른 2시간 간격으로 측정한 상처 회복 결과를 나타낸 그래프이다.5 is a graph showing wound recovery results measured at 2 hour intervals according to Experimental Example 2.
도 6은 실험예 2에 따른 처리 16시간 후 상처 회복 결과를 나타낸 그래프이다.6 is a graph showing the wound recovery results after 16 hours of treatment according to Experimental Example 2.
도 7은 실험예 2에 따른 0시간 및 처리 16시간 후 상처 회복 결과를 나타낸 현미경 사진이다.7 is a micrograph showing the wound recovery results after 0 hours and 16 hours treatment according to Experimental Example 2.
도 4 내지 도 7에서 볼 수 있듯이, 복사나무 수지를 처리할 경우 세포 이동에 의해 상처 회복 효과가 나타났다. 또한, 복사나무 수지를 병풀추출물 및 마데카소사이드와 함께 처리할 경우 시너지적 상처 회복 효과가 나타남을 확인하였다. 특히, 복사나무 수지 100 ppm, 병풀추출물 10 ppm, 마데카소사이드 10 ppm 및 스타필로코커스 에피데르미디스(Staphylococcus epidermidis) 균주 배양액 1%(v/v)를 함께 처리할 경우 각각을 단독으로 처리한 경우에 비해 시너지적 상처 회복 효과가 우수함을 확인하였다.As can be seen in FIGS. 4 to 7, when the radiation tree resin is treated, the wound healing effect was exhibited by cell migration. In addition, it was confirmed that a synergistic wound recovery effect appeared when the radix tree resin was treated with centella asiatica extract and madecassoside. In particular, 100 ppm of radix tree resin, 10 ppm of centella asiatica extract, 10 ppm of madecassoside, and 1% (v/v) of the strain culture solution of Staphylococcus epidermidis were treated together. Compared to the case, it was confirmed that the synergistic wound healing effect was excellent.
따라서, 복사나무 수지는 피부 재생, 주름 개선, 상처 개선 또는 치유 효과를 가지는 것을 알 수 있었다.Therefore, it was found that the radiant tree resin has skin regeneration, wrinkle improvement, wound improvement or healing effect.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200054728A KR102176883B1 (en) | 2020-05-07 | 2020-05-07 | Composition for skin regeneration, anti-wrinkle, or wound healing containing Prunus persica resin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200054728A KR102176883B1 (en) | 2020-05-07 | 2020-05-07 | Composition for skin regeneration, anti-wrinkle, or wound healing containing Prunus persica resin |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102176883B1 true KR102176883B1 (en) | 2020-11-11 |
Family
ID=73451684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200054728A KR102176883B1 (en) | 2020-05-07 | 2020-05-07 | Composition for skin regeneration, anti-wrinkle, or wound healing containing Prunus persica resin |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102176883B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210118030A (en) * | 2019-08-27 | 2021-09-29 | 코스맥스 주식회사 | A genus of Staphylococcus strain and uses thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050070873A (en) * | 2003-12-31 | 2005-07-07 | 주식회사 두산 | Composition for activation of estrogen secretion, method to activate the secretion of estrogen, composition for promotion of collagen synthesis and method to promote the synthesis of collagen |
KR20110103603A (en) * | 2010-03-15 | 2011-09-21 | 주식회사 엘씨에스바이오텍 | Composition for protecting and improving skin |
CN105362116A (en) * | 2014-10-28 | 2016-03-02 | 刘朦诗 | Comprehensive-effect mask free of chemical addition and preparation method thereof |
CN106137928A (en) * | 2016-08-25 | 2016-11-23 | 青岛海澄知识产权事务有限公司 | A kind of preparation method of Resina persicae facial film |
CN110812307A (en) * | 2018-08-14 | 2020-02-21 | 南京昕海医药科技有限公司 | External preparation with whitening and anti-wrinkling functions |
-
2020
- 2020-05-07 KR KR1020200054728A patent/KR102176883B1/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050070873A (en) * | 2003-12-31 | 2005-07-07 | 주식회사 두산 | Composition for activation of estrogen secretion, method to activate the secretion of estrogen, composition for promotion of collagen synthesis and method to promote the synthesis of collagen |
KR20110103603A (en) * | 2010-03-15 | 2011-09-21 | 주식회사 엘씨에스바이오텍 | Composition for protecting and improving skin |
CN105362116A (en) * | 2014-10-28 | 2016-03-02 | 刘朦诗 | Comprehensive-effect mask free of chemical addition and preparation method thereof |
CN106137928A (en) * | 2016-08-25 | 2016-11-23 | 青岛海澄知识产权事务有限公司 | A kind of preparation method of Resina persicae facial film |
CN110812307A (en) * | 2018-08-14 | 2020-02-21 | 南京昕海医药科技有限公司 | External preparation with whitening and anti-wrinkling functions |
Non-Patent Citations (2)
Title |
---|
Xing-Cun Yao et al., "Antioxidant Activity and Antibacterial Activity of Peach Gum Derived Oligosaccharides", International journal of biological macromolecules, Vol. 62 (2013) |
인터넷검색 : 유튜브게시글 <https://www.youtube.com/watch?v=OwCkSYDubaw> * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210118030A (en) * | 2019-08-27 | 2021-09-29 | 코스맥스 주식회사 | A genus of Staphylococcus strain and uses thereof |
KR102456734B1 (en) | 2019-08-27 | 2022-10-20 | 코스맥스 주식회사 | A genus of Staphylococcus strain and uses thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101809754B1 (en) | Composition for improving skin wrinkle and enhancing elasticity | |
KR102042967B1 (en) | Cosmetic composition for anti-aging comprising fucosyllactose | |
US20210330575A1 (en) | Cosmetic composition for skin whitening and wrinkle improvement comprising adventitious root extract of centella asiatica as effective ingredient | |
KR102113193B1 (en) | Composition for improving skin conditions comprising artemisiae annuae herba, centella asiatica and green tea extract or fraction thereof and method for improving skin conditions using the same | |
KR101898688B1 (en) | Composition for preventing, treating or improving muscle atrophy comprising complex extracts | |
KR102117218B1 (en) | Composition for improving skin beauty comprising extract of fermented soybean fermented with Aspergillus cristatus strain | |
KR102176883B1 (en) | Composition for skin regeneration, anti-wrinkle, or wound healing containing Prunus persica resin | |
KR20120131065A (en) | The composition comprising the extract or fraction of Pleurotus eryngii var. ferulae for prevention of anti aging as an active ingredient | |
KR102178890B1 (en) | Composition for promoting synthesis of hyaluronic acid comprising Portulacae Herba extracts and the use thereof | |
KR102462347B1 (en) | Cosmetic composition for improving skin barrier function and anti-wrinkle effects comprising fermented eggplant extract as an active ingredient | |
KR102379698B1 (en) | A composition for skin whitening or regeneration comprising Melandrium firmum extract | |
KR102139156B1 (en) | Composition Comprising Enzyme Treated Extract of Red Ginseng and Gastrodia for Preventing or Improving Skin Wrinkle as Active Ingredient | |
KR101994618B1 (en) | A composition for skin smoothing comprising an extract of fermented ponciri fructus | |
KR102011639B1 (en) | Composition for anti-oxidant, skin whitening and anti-wrinkle effect comprising Glehnia Radix leaf extract as effective component | |
KR20160054672A (en) | Composition for promoting synthesis of hyaluronic acid comprising Hordeum vulgare extracts and the use thereof | |
KR20210025316A (en) | Composition for improving skin beauty comprising extract of fermented roots of Panax notoginseng by Aspergillus cristatus strain | |
KR20180104960A (en) | Composition comprising extracts of banana, cherry, and walnut for anti-skin aging | |
KR20160054681A (en) | Composition for promoting synthesis of hyaluronic acid comprising Polygala tenuifolia Willd extracts and the use thereof | |
KR102204368B1 (en) | Composition for promoting synthesis of hyaluronic acid comprising jujube extracts and the use thereof | |
KR102012170B1 (en) | Composition comprising extracts of banana, cherry, and walnut for anti-skin aging | |
KR102628844B1 (en) | Cosmetic composition for anti-oxidation, skin whitening and anti-wrinkle containing a mixed fermentation extracts of Wisteria floribunda flowers, Aralia elata flowers, Camellia japonica leafs and Camellia japonica flowers as effective component | |
KR102586125B1 (en) | Antioxidant, anti-inflammatory and skin anti-aging composition comprising nano-liposome containing complex plant extracts as active ingredients | |
KR102484422B1 (en) | Cosmetic composition comprising extract of Cactus and fermented product of Lactobacillus | |
KR102284803B1 (en) | Composition for slimming containing complex extracts of redbeet and red onion | |
KR102284805B1 (en) | Composition for slimming containing complex extracts of redbeet and cabbage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |